Cystic Fibrosis Therapeutics Market Size - By Treatment Method (Medications [Drug Class {CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements}, Route of Administration], Devices), Distribution Channel & Forecast, 2021 - 2027

Cystic Fibrosis Therapeutics Market Size

Cystic Fibrosis Therapeutics Market size exceeded USD 8.5 billion in 2020 and is anticipated to grow at over 16.1% CAGR from 2021 to 2027. Growing awareness about the potential threat of cystic fibrosis, rise in the adoption of drug therapies and increasing prevalence of cystic fibrosis across the globe, are some of the prominent factors that drive the market growth. There was no considerable impact of COVID-19 on the cystic fibrosis therapeutics industry, since several countries adopted lockdown and cancelled routine clinic appointments to prevent unnecessary hospital visits and viral spread. The market witnessed a short-term disruption during the initial days of the COVID-19 pandemic due to decline in non-urgent in-person clinic visits.
 

Cystic Fibrosis Therapeutics Market Trends

Growing awareness in the emerging countries regarding the oral drug treatments such as pancreatic enzyme supplements and CFTR modulators for cystic fibrosis and their cost affordability is a major factor that is expected to foster the market progression. Cystic fibrosis is an inherited disorder that damage lungs and body organ. Numerous healthcare organizations, and medical institutes spread awareness about the treatment of cystic fibrosis to enhance public health. The Cystic Fibrosis Foundation, spread awareness about cystic fibrosis through social media, sharing personal stories about diagnosis, various treatments, and many more.
 

Increasing awareness among patient population and healthcare professionals about the availability of advanced medications in the market and their benefits over the present drug product portfolio is poised to boost the market over the forecast period. Furthermore, rising prevalence of cystic fibrosis disease in developed countries such the U.S., is increasing demand and usage of technologically advanced medications for cystic fibrosis will augment the industry growth.
 

Cystic Fibrosis Therapeutics Market Analysis

The medication segment in the cystic fibrosis therapeutics market accounted for around USD 6.1 billion in 2020. The medications such as aerosolized antibiotic, bronchodilators, mucus thinner, and CFTR modulator among others helps to reduce lung flare-ups, respiratory symptoms, and enhanced patients' short-term quality of life. Such factors increase the demand for medications. Other factors such as rising demand as well as awareness about the advanced medications helps to stimulate the industry expansion. New product launches and regulatory approvals for commercialization of cystic fibrosis therapeutics will further impact the industry progression.
 

The hospital segment will capture 49% of the cystic fibrosis therapeutics market share from 2021 to 2027 led by the rising prevalence of cystic fibrosis and need for precise diagnosis and follow-up treatments under the supervision of physicians. This increases the patient hospital visits accelerating the segment growth. Additionally, revenue generated by hospital pharmacies is relatively high because infected people commonly visit nearby hospitals for doctor's prescription medicines and appointment.
 

North America cystic fibrosis therapeutics market held over 76% of revenue share in 2020 impelled by the increasing incidence of cystic fibrosis and the availability of several treatment options in the region. Moreover, rising government initiative such as increasing funding for innovations and R&D projects on cystic fibrosis drug drives the industry revenue. For instance, North American Cystic Fibrosis Conference (NACFC) offer educational forum to cystic fibrosis specialists to share developments in R&D related to cystic fibrosis therapeutics. Other factors such as, well established healthcare infrastructure, presence of major market leaders and reimbursements will propel the North America market demand over the forecast timeframe.
 

Cystic Fibrosis Therapeutics Market Share

Some of the prominent companies operating in the market are:

• Vertex Pharmaceutical Incorporated
• Roche
• Nestle Health Science
• AbbVie
• Viatris Inc.
• Horizon Therapeutic Plc.
• Gilead Sciences
• Chiesi Farmacrutici
• Pharmaxis Ltd.
• Teva Pharmaceuticals.

These market participants are implementing various growth strategies to sustain the industry competition.
 

Some of the recent industry developments:

• In October 2020, Roche announced the partnership with AbbVie and acquired TMEM16A potentiators portfolio, for the treatment of cystic fibrosis patients irrespective of CFTR genotype and other respiratory illnesses. The partnership helped the firm to influence their product portfolio growth.
   
• In October 2019, AbbVie and The Cystic Fibrosis Foundation have formed a strategic partnership to develop a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator molecule.  This partnership enabled the company to increase their product portfolio.
   

The cystic fibrosis therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Method, 2016-2027 (USD Million)

• Medications 
  • Drug Class
    • CFTR modulators
    • Mucolytics
    • Bronchodilators
    • Pancreatic enzyme supplements
    • Others
• Route of Administration
  • Oral drugs
  • Inhaled drugs
• Devices
• Others

Market, By Distribution Channel, 2016-2027 (USD Million)

• Hospital
• Retail pharmacies
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Rest of World
  • Australia
  • South Africa
  • Others